camptothecin has been researched along with maytansine in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Adamson, RH; Mead, JA; Sieber, SM | 1 |
| Wall, ME; Wani, MC | 1 |
| Li, HL; Liao, K; Liu, R; Liu, SJ; Wang, HH; Wang, JZ; Wang, Q; Zhang, Y | 1 |
| Wright, J | 1 |
| Abe, Y; Agatsuma, T; Aida, T; Arakawa, S; Atsumi, R; Hagihara, K; Harada, N; Hayakawa, I; Hirai, T; Ishii, C; Nakada, T; Ogitani, Y; Oitate, M; Okamoto, H; Soma, M; Yamaguchi, J | 1 |
| Agatsuma, T; Hagihara, K; Naito, H; Ogitani, Y; Oitate, M | 1 |
| Atreya, C; Korn, WM; Parikh, A; Venook, AP | 1 |
| Maenishi, O; Nakagawa, K; Nishio, K; Nonagase, Y; Ogitani, Y; Sakai, K; Takegawa, N; Tamura, T; Tsurutani, J; Yonesaka, K | 1 |
| Lee, EK; Liu, JF | 1 |
| Gelmon, KA; Tesch, ME | 1 |
| Hugo, HS | 1 |
| Funasaka, C; Harano, K; Hosono, A; Ishii, G; Kondoh, C; Kusuhara, S; Matsubara, N; Mitsunaga, S; Mukohara, T; Naito, Y; Nakai, T; Nakajima, H; Nakao, T | 1 |
4 review(s) available for camptothecin and maytansine
| Article | Year |
|---|---|
Pharmacology of antitumor agents from higher plants.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aporphines; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Etoposide; Humans; Leukemia L1210; Leukemia, Experimental; Leukemia, Lymphoid; Maytansine; Melanoma; Naphthoquinones; Nasopharyngeal Neoplasms; Neoplasms; Neoplasms, Experimental; Phenanthrenes; Structure-Activity Relationship; Teniposide; Vinblastine; Vincristine | 1976 |
Antineoplastic agents from plants.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemical Phenomena; Chemistry; Diterpenes; Harringtonines; Isoquinolines; Maytansine; Phenanthridines; Structure-Activity Relationship; Triterpenes | 1977 |
Antibody-drug conjugates in gynecologic malignancies.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; CA-125 Antigen; Camptothecin; Cell Adhesion Molecules; Drug Design; Female; Folate Receptor 1; Genital Neoplasms, Female; GPI-Linked Proteins; Humans; Immunoconjugates; Maytansine; Membrane Proteins; Mesothelin; Sodium-Phosphate Cotransporter Proteins, Type IIb; Thromboplastin | 2019 |
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunoconjugates; Lapatinib; Mastectomy; Maytansine; Medical Oncology; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxazoles; Practice Guidelines as Topic; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2020 |
9 other study(ies) available for camptothecin and maytansine
| Article | Year |
|---|---|
Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors.
Topics: Animals; Annexin A5; Apoptosis; beta Catenin; Camptothecin; Caspase 3; Cell Line, Tumor; Cytochromes c; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Green Fluorescent Proteins; Hippocampus; Humans; Maytansine; Mice; Mice, Transgenic; Mutation; Neuroblastoma; RNA, Small Interfering; Staurosporine; Subcellular Fractions; tau Proteins; Time Factors; Transfection; Tumor Suppressor Protein p53 | 2010 |
Nanotechnology: Deliver on a promise.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Brentuximab Vedotin; Camptothecin; Cyclodextrins; Doxorubicin; Drug Delivery Systems; Humans; Immunoconjugates; Maytansine; Molecular Targeted Therapy; Nanomedicine; Nanoparticles; Polyethylene Glycols; Trastuzumab | 2014 |
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Female; Histones; Humans; Immunoconjugates; Macaca fascicularis; Maytansine; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Receptor, ErbB-2; Topoisomerase I Inhibitors; Trastuzumab | 2016 |
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Bystander Effect; Camptothecin; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Female; Humans; Immunoconjugates; Maytansine; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Receptor, ErbB-2; Stomach Neoplasms; Topoisomerase I Inhibitors; Trastuzumab | 2016 |
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Chemoradiotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fluorouracil; Gene Amplification; High-Throughput Nucleotide Sequencing; Humans; Laparoscopy; Leucovorin; Liver Neoplasms; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Off-Label Use; Palliative Care; Proto-Oncogene Proteins c-myc; Receptor, ErbB-2; Tomography, X-Ray Computed; Trastuzumab; Tumor Suppressor Protein p53; Ultrasonography | 2017 |
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Immunoconjugates; Maytansine; Mice; Mice, Inbred BALB C; Mice, Nude; Multidrug Resistance-Associated Protein 2; Random Allocation; Receptor, ErbB-2; Stomach Neoplasms; Topoisomerase I Inhibitors; Trastuzumab | 2017 |
Update on antibody-drug conjugates in breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Maytansine; Trastuzumab | 2021 |
Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Maytansine; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2022 |
Trastuzumab deruxtecan beats trastuzumab emtansine in lowered disease progression, death.
Topics: Ado-Trastuzumab Emtansine; Breast Neoplasms; Camptothecin; Disease Progression; Female; Humans; Immunoconjugates; Maytansine; Receptor, ErbB-2; Trastuzumab | 2022 |